Multi-Center phase II study for combination therapy with paclitaxel/ doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302)

Japanese Journal of Clinical Oncology

Volumn 38, Issue 3, 2008, Pages 176-181

  Takiuchi, Hiroya ^a   Goto, Masahiro ^a   Imamura, Hiroshi ^b   Furukawa, Hiroshi ^b   Imano, Motohiro ^c   Imamoto, Haruhiko ^c   Kimura, Yutaka ^d   Ishida, Hideyuki ^e   Fujitani, Kazumasa ^f   Narahara, Hiroyuki ^g   Shimokawa, Toshio ^h  

^a OSAKA MEDICAL COLLEGE HOSPITAL   (Japan)

^b Sakai City Medical Center   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d OSAKA POLICE HOSPITAL   (Japan)

^e Osaka Seamen's Insurance Hospital   (Japan)

^f OSAKA NATIONAL HOSPITAL   (Japan)

^g OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^h Osaka Gastrointestinal Cancer Chemotherapy Study Group   (Japan)

Author keywords

Doxifluridine; Gastric cancer; Paclitaxel; S 1; Second line chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DOXIFLURIDINE; FULTURON; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FLOXURIDINE; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BILE REFLUX; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GLOSSITIS; HUMAN; INFECTION; INOPERABLE CANCER; LACRIMATION; LIVER METASTASIS; LOW BACK PAIN; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SIDE EFFECT; SKIN DISEASE; STOMACH CANCER; STOMACH DISCOMFORT; STOMATITIS; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; ADENOCARCINOMA; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG RESISTANCE; LIVER TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PERITONEUM TUMOR; STOMACH TUMOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOXURIDINE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; OXONIC ACID; PACLITAXEL; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; THROMBOCYTOPENIA;

EID: 40749095281     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn003     Document Type: Article

References (16)

1. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluoreuracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
2. Murad A, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-FU, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3. Grimelius B, Ekström Y, Hoffman Y, Graf W, Sjödén PO, Haglund U, et al., Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
4. Kunisaki C, Imada T, Yamada R, Hatori S, Orlo H, Otsuka Y, et al. Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma. Anticancer Res 2005;25:2973-7.
5. Kim H, Park JH, Bang SJ, Kim DH, Cho Hit, Kim GY, et al. A phase II study of doe6taxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment. Jap J Clin Oncol 2005;35-727-32.
6. Giuliani F, Molica S, Maiello E, Battaglia C, Gebbia V, Di Bisceglie M, or al. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: A phase II study of the Gruppo Oncologico, dell' Italia Meridionale (prot. 2106). Am J Clin Oncol 2005;28:581-5.
7. Sasako M, Yamaguchi T, Kinoshiva T, Fujii M, Nashimoto A, Furukawa K et al. Randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients (pts) after curative D2 gastrectomy (ACTS-GC study). Abstract No 8. Gastrointestinal Cancers Symposium 2007.
8. Sawda N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Introduction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-9.
9. Sawada N, Nose T, Ishikawa, T, Yutaka T. Enhancement of antitumor activity of 5′-dcoxy-5-fluorouridine (Furtulon) by taxane in human gastric cancer xenografts. Oncol Rep 2005;14:53-7.
10. Moriwaki T, Hyodo I, Nishina T, Hirao K, Tsuzuki T, Hidaka S, et al. A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer. Cancer Chemother Pharmacol 2005;56:138-44.
11. Ohtsu A, Shimada, Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with advanced gastric cancer. JCOG study 9205. J CJin Oncol 2003;21:54-9.
12. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose Methatrexate, fluorouracil, and doxorubicin versus infusional fluorouracil and cisplatin in advanced gawic cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 2000;18:2648-57.
13. Van Cutsem E, Moiseyenko, VM, Tjulandin S, Majlis A, Constenta M, Boni C, et al. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. J Clin Oncol 2006;24:4991-7.
14. Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F, et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. Abstract No: 4017 Proc Am Soci Clin Oncol 2006;25.
15. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, et al. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002;5:90-5.
16. Yamada Y, thirao K, Ohtsu A, Boku N, Hyodo, Saitoh H, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric canaer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001;12:1133-7.